Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Antonia, S.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K. H.; De Wit, M.; Cho, B. C.; Bourhaba, M.; Quantin, X.; Tokito, T.; Mekhail, T.; Planchard, D.; Kim, Y.; Karapetis, C.; Hiret, S.; Ostoros, G.; Kubota, K.; Gray, J.; Paz-Ares, L.; Carpeno, J. De Castro; Faivre-Finn, C.; Reck, M.; Vansteenkiste, J.; Spigel, D.; Wadsworth, C.; Taboada, M.; Dennis, P.; Ozguroglu, M.

authors

Publication Date

  • October 1, 2018

webpage

published in

category

keywords

  • NSCLC
  • PACIFIC
  • durvalumab

start page

  • S184

end page

  • S184

volume

  • 13

issue

  • 10